Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16737
Title: Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy
Austin Authors: Lin, M;Todaro, M;Chan, J ;Churilov, Leonid ;Zhu, WS;Ramdave, Shankar;Mitchell, PJ;Dowling, RJ;Kwan, Patrick;Yan, Bernard
Affiliation: Melbourne Brain Centre, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
Department of Radiology, The Royal Melbourne Hospital, the University of Melbourne, Parkville, Victoria, Australia
Department of Neurology, The Royal Melbourne Hospital, the University of Melbourne, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Florey Institute of Neurosciences and Mental Health, Melbourne Brain Centre, Heidelberg, Victoria, Australia
Issue Date: Jan-2016
metadata.dc.date: 2015-09-03
Publication information: American Journal of Neuroradiology 2016; 37(1): 108-13
Abstract: BACKGROUND AND PURPOSE: Differing responses to clopidogrel following endovascular treatment of cerebrovascular diseases may increase the risk of vascular complications. CYP2C19 gene polymorphisms influence clopidogrel activity. We aimed to study the clinical impact of CYP2C19 gene polymorphisms in patients undergoing endovascular treatment. MATERIALS AND METHODS: This was a prospective, longitudinal, observational study. Information on demographics and cerebrovascular status was collected as baseline. Clopidogrel response was tested by the VerifyNow P2Y12 assay. CYP2C19 genotyping was undertaken by polymerase chain reaction-restriction fragment length polymorphism. Three-month follow-up data included vascular complications, mortality, and modified Rankin Scale score. Associations were investigated among CYP2C19 genotypes, clopidogrel responsiveness, and clinical outcomes. RESULTS: One hundred and eight participants were included. Median age was 56 years (interquartile range, 48.8-65.0 years), and 35 (32.4%) were male. Forty-four participants were classified into group 1 (homozygous CYP2C19*1/*1); 31, into group 2 (25 with CYP2C19*1/*2, two with CYP2C19*1/*3, three with CYP2C19*3/*3, one with CYP2C19*2/*3); 28, into group 3 (24 with CYP2C19*1/*17, four with CYP2C19*17/*17); and 5, into group 4 (CYP2C19*2/*17). A significantly higher proportion of participants in group 3 experienced ischemic events (9 of 28, 32.1%) compared with group 1 (5 of 44, 11.4%; P = .04; odds ratio, 3.7; 95% confidence interval, 1.1-12.6). There was no significant difference in clopidogrel response among the 4 genotype groups. CONCLUSIONS: Individuals with CYP2C19*17 may have increased risk of ischemic events following endovascular treatment, independent of clopidogrel responsiveness. Larger studies are required to confirm the influence of CYP2C19*17 on clinical outcomes and to understand the mechanisms for increased ischemic events.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16737
DOI: 10.3174/ajnr.A4481
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26338921
Type: Journal Article
Subjects: Brain Ischemia
Cerebrovascular Disorders
Cytochrome P-450 CYP2C19
Endovascular Procedures
Genotype
Genetic Predisposition to Disease
Ticlopidine
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.